TY - JOUR
T1 - Cutaneous T cell Lymphoma
T2 - an Update on Pathogenesis and Systemic Therapy
AU - Chung, Catherine G.
AU - Poligone, Brian
N1 - Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of MF and SS have broadened the therapeutic targets; here, we review emerging concepts in the pathogenesis of MF and SS as well as novel and traditional systemic therapies for MF and SS. These include histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, and belinostat), monoclonal antibodies (alemtuzumab, brentuximab vedotin, and mogamulizumab) and single-agent cytotoxic chemotherapeutic agents (e.g., pralatrexate, doxorubicin, bendamustine, and forodesine), as well as multi-agent chemotherapy regimens.
AB - Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of MF and SS have broadened the therapeutic targets; here, we review emerging concepts in the pathogenesis of MF and SS as well as novel and traditional systemic therapies for MF and SS. These include histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, and belinostat), monoclonal antibodies (alemtuzumab, brentuximab vedotin, and mogamulizumab) and single-agent cytotoxic chemotherapeutic agents (e.g., pralatrexate, doxorubicin, bendamustine, and forodesine), as well as multi-agent chemotherapy regimens.
UR - http://www.scopus.com/inward/record.url?scp=84949519133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949519133&partnerID=8YFLogxK
U2 - 10.1007/s11899-015-0293-y
DO - 10.1007/s11899-015-0293-y
M3 - Review article
C2 - 26626770
AN - SCOPUS:84949519133
SN - 1558-8211
VL - 10
SP - 468
EP - 476
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 4
ER -